People · Operator
Named in public records as an officer, director or promoter · active 2010–2012 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| CeloNova BioSciences, Inc. | — | Biotechnology | Series B | $20.8M | $827.2M | 2011 |
| BioNumerik Pharmaceuticals, Inc. | — | Pharmaceuticals | Series A | $11.3M | $315.6M | 2010 |
Dennert O. Ware at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Dennert O. Ware on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Harry R. Jacobson | 2 | 7 |
| Thomas W. Lyles, Jr. | 1 | 4 |
| Homer L. Pearce | 1 | 3 |
| James R. Leininger | 1 | 2 |
| David R. Margrave | 1 | 1 |
| Steve W. Carchedi | 1 | 1 |
| Stacey R. Bain | 1 | 1 |
| Delores P. Williams | 1 | 1 |
| Michael W. Grunze | 1 | 1 |
| Goetz W. Richter | 1 | 1 |
| Frederick H. Hausheer | 1 | 1 |
| John W. Yarbro | 1 | 1 |
| Harry R. Kochat | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.